ivermectin b1a

Ivermectin B1a is the major (80%) component of commercially available ivermectin and a derivative of Avermectin B1a.

Ivermectin B1a aglycone is an acid degradation product produced by hydrolysis of the disaccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity.

Ivermectin B1a monosaccharide is produced by selective hydrolysis of the terminal saccharide unit of ivermectin. It can inhibit nematode larval development, but does not cause paralytic activity. This compound has been used as a probe to detect some types of ivermectin resistance.

epi-Ivermectin B1a is a significant impurity related to Ivermectin, typically found as a process-related impurity or potential degradation product in antiparasitic formulations. It is also utilized in research on both in vivo and in vitro parasites in cattle.

Deuterated ivermectin B1a

Ivermectin B1a-d2-1 is the deuterium-labeled form of Ivermectin B1a. As a derivative of Avermectin B1a, Ivermectin B1a constitutes the primary component of Ivermectin. Ivermectin (MK-933) is a broad-spectrum antiparasitic agent and is also being considered as a candidate active molecule in the treatment of SARS-CoV-2/COVID-19.